Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 4/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.48 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.47 |
| ▸ | SCD | O00767 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3773985 | 0.91 | HRH3 (0.50) | HPGDSHRH3CXCR3SCDALDH1A1 | |
| SCHEMBL13006725 | 0.91 | HRH3 (0.49) | HPGDSHRH3CXCR3SCDALDH1A1 | |
| SCHEMBL3773296 | 0.89 | HRH3 (0.52) | HPGDSHRH3CXCR3ALDH1A1SMN1; SMN2 | |
| SCHEMBL3767449 | 0.88 | HRH3 (0.49) | HPGDSHRH3CXCR3ALDH1A1SMN1; SMN2 | |
| SCHEMBL3774853 | 0.87 | HRH3 (0.50) | HPGDSHRH3CXCR3SCDALDH1A1 | |
| SCHEMBL3766163 | 0.87 | HRH3 (0.53) | HPGDSHRH3CXCR3HDAC1 | |
| SCHEMBL3761209 | 0.86 | HRH3 (0.49) | HPGDSHRH3CXCR3SCDALDH1A1 | |
| SCHEMBL3765378 | 0.86 | ALDH1A1 (0.48) | HPGDSHRH3CXCR3ALDH1A1SMN1; SMN2 | |
| SCHEMBL3761300 | 0.86 | HRH3 (0.47) | HPGDSHRH3CXCR3ALDH1A1SMN1; SMN2 | |
| SCHEMBL3767753 | 0.86 | HPGDS (0.53) | HPGDSHRH3ALDH1A1HDAC1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7851474-B2 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION (US) | 2010-12-14 | — | — | US | disclosed |
| US-7851474-B2 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION (US) | 2010-12-14 | — | — | US | disclosed |
| US-20070049571-A1 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION | 2007-03-01 | — | — | US | disclosed |
| US-20070049571-A1 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION | 2007-03-01 | — | — | US | disclosed |
| WO-2007016496-A2 | DIPIPERAZINYL KETONES AND RELATED ANALOGUES | NEUROGEN CORPORATION (US) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049571-A1 | Dipiperazinyl ketones and related analogues | HRH4, HRH3, HRH1 | HPGDS 611/4885HRH3 2/4885CXCR3 717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.